Rapid Micro Biosystems (RPID) Preferred Stock Liabilities (2020 - 2021)
Rapid Micro Biosystems (RPID) reported Preferred Stock Liabilities of $235.8 million for Q2 2021, up 60.1% on a YoY basis from $147.3 million in Q2 2020, and up 0.86% sequentially from $233.8 million in Q1 2021.
Rapid Micro Biosystems (RPID) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Rapid Micro Biosystems (RPID) has 2 years of Preferred Stock Liabilities data on file, last reported at $235.8 million in Q2 2021.
- For the quarter ending Q2 2021, Preferred Stock Liabilities rose 60.1% year-over-year to $235.8 million; the trailing twelve-month figure through Jun 2021 stood at $235.8 million (up 60.1% YoY), and the FY2020 full-year result was $151.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $235.8 million in Q2 2021, from $233.8 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $235.8 million in Q2 2021 to a low of $147.3 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Rapid Micro Biosystems | 90.41 Mn | 80.98 Mn | 371,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 235.84 Mn |
| Mar 31, 2021 | 233.83 Mn |
| Dec 31, 2020 | 151.83 Mn |
| Sep 30, 2020 | 149.55 Mn |
| Jun 30, 2020 | 147.31 Mn |